Anderson Lab technology plays a crucial role in the development of a new combinatorial therapy for liver cancer. In a study published in Molecular Therapy, the group’s lipid nanoparticles were used in conjunction with siRNA and chemotherapy to target key proteins involved in cell death, selectively killing cancer cells in animal models.